Profil
F.
Andrew Dorr served as the Chief Medical Officer at Ionis Pharmaceuticals, Inc. from 1996 to 2003.
He then worked as the Chief Operating Officer at Salmedix, Inc. in 2004.
Later, he became the Chief Medical Officer at Spyre Therapeutics, Inc. Dr. Dorr received his undergraduate degree from Davidson College and his doctorate from The University of North Carolina at Charlotte.
Anciens postes connus de F. Andrew Dorr
| Sociétés | Poste | Fin |
|---|---|---|
| SPYRE THERAPEUTICS, INC. | Directeur Technique/Scientifique/R&D | 21/04/2017 |
Salmedix, Inc.
 Salmedix, Inc. Pharmaceuticals: MajorHealth Technology Salmedix, Inc. develops oncology and small molecule drugs to treat hematological malignancies. The company's product, Treanda, is currently in Phase II clinical trials in the United States and Canada for the treatment of indolent (slowly progressing) non-Hodgkin's lymphoma. It was founded in 2000 and is located in San Diego, CA. | Directeur des opérations | 01/08/2004 |
| IONIS PHARMACEUTICALS, INC. | Directeur Technique/Scientifique/R&D | 01/01/2003 |
Formation de F. Andrew Dorr
| Davidson College | Undergraduate Degree |
| The University of North Carolina at Charlotte | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| SPYRE THERAPEUTICS, INC. | Health Technology |
| IONIS PHARMACEUTICALS, INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Salmedix, Inc.
Salmedix, Inc. Pharmaceuticals: MajorHealth Technology Salmedix, Inc. develops oncology and small molecule drugs to treat hematological malignancies. The company's product, Treanda, is currently in Phase II clinical trials in the United States and Canada for the treatment of indolent (slowly progressing) non-Hodgkin's lymphoma. It was founded in 2000 and is located in San Diego, CA. | Health Technology |